Most of these drugs are not currently used in clinical practice yet but are subject to clinical trials: one of the most promising is Selumetinib, a MEK inhibitor (a downstream protein in RAS pathway), which has proven effectiveness in neurofibromas and low-grade gliomas. This evidence concerns the gene MAP2K7 and glioma.